VALIANT LABORATORIES LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148.9 INR | -3.22% |
|
-5.61% | -14.03% |
Income Statement Evolution (Annual data)
| Fiscal Period: Maart | 2023 |
|---|---|
| Net sales 1 | 5,009 |
| EBITDA 1 | 523.8 |
| EBIT 1 | 502.9 |
| Operating Margin | 10.04% |
| Earnings before Tax (EBT) 1 | 572 |
| Net income 1 | 435 |
| Net margin | 8.68% |
| EPS 2 | 13.36 |
| Free Cash Flow 1 | 213.8 |
| FCF margin | 4.27% |
| FCF Conversion (EBITDA) | 40.81% |
| FCF Conversion (Net income) | 49.15% |
| Dividend per Share | - |
| Announcement Date | 6/8/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 |
|---|---|
| Net Debt 1 | 249 |
| Net Cash position 1 | - |
| Leverage (Debt/EBITDA) | 0.4745 x |
| Free Cash Flow 1 | 214 |
| ROE (net income / shareholders' equity) | 50.6% |
| ROA (Net income/ Total Assets) | 16.2% |
| Assets 1 | 2,680 |
| Book Value Per Share 2 | 30.90 |
| Cash Flow per Share 2 | 0.3900 |
| Capex 1 | 565 |
| Capex / Sales | 11.28% |
| Announcement Date | 6/8/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.03% | 76.15M | |
| +1.61% | 49.2B | |
| +16.33% | 41.24B | |
| +18.68% | 25.89B | |
| +12.78% | 19.81B | |
| +0.85% | 17.48B | |
| -21.87% | 15.86B | |
| +2.32% | 15.35B | |
| -10.29% | 15.23B | |
| -22.30% | 13.36B |
- Stock Market
- Equities
- VALIANTLAB Stock
- Financials Valiant Laboratories Limited
